Development and Implementation of a Piperacillin-Tazobactam Extended Infusion Guideline

Journal of Pharmacy Practice

Volumn 24, Issue 6, 2011, Pages 571-576

  Heinrich, Lynley S ^a   Tokumaru, Sheri ^b   Clark, Nina M ^a   Garofalo, John ^a   Paek, Jamie L ^a   Grim, Shellee A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

antibiotics; extended infusion; guideline

Indexed keywords

CEFEPIME; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ARTICLE; COST CONTROL; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INFUSION; DRUG MONITORING; EXTENDED INFUSION; HOSPITAL INFECTION; HUMAN; INFUSION RATE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHARMACIST; PHARMACY; PNEUMONIA; PRACTICE GUIDELINE; PSEUDOMONAS INFECTION; THROMBOCYTOPENIA;

EID: 84856062552     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190011406984     Document Type: Article

References (13)

1. Gaynes R, Edwards JR. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram negative bacilli. Clin Infect Dis. 2005 ; 41 (6). 848-854 (Pubitemid 41266753)
2. Osmon S, Ward S, Fraser VJ, et al. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest. 2004 ; 125 (2). 607-616 (Pubitemid 38223643)
3. Kang C, Kim S, Kim H, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003 ; 37 (6). 745-751 (Pubitemid 37153651)
4. Livermore DM. Multiple mechanisms of antimicrobial resistance in pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis. 2002 ; 34 (5). 634-640 (Pubitemid 34165326)
5. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004 ; 32 (8). 470-485
6. Boucher HW, Talbot GH, Bradley , et al. Bad bugs, no drugs: no ESKAPE! An Update from the Infectious Diseases Society of America. CID. 2009 ; 48 (1). 1-12
7. Gales AC, Jones RN, Turnidge J, et al. Characterization of pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program. Clin Infect Dis. 2001 ; 32 (suppl 2). S146 - S155 (Pubitemid 32424268)
8. Micromedex Healthcare Series Web site. http://www.thomsonhc.com.ezproxy. samford.edu/home/dispatch. Accessed February 7, 2011.
9. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on ß-lactam antibiotics. Pharmacotherapy. 2006 ; 26 (9). 1320-1332
10. Kim A, Sutherland C, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment of pseudomonas aeruginosa infections: prolonged or continuous infusion?. Pharmacotherapy. 2007 ; 27 (11). 1490-1497 (Pubitemid 350060204)
11. Lodise TP, Lomaestro BM, Drusano GL. Piperacillin-tazobactam for pseudomonas aeruginosa infection: Clinical implications of an extended infusion dosing strategy. Clin Infect Dis. 2007 ; 44 (3). 357-363 (Pubitemid 46147617)
12. Patel GW, Patel N, Lat A, et al. Outcomes of extended infusion piperacillin/tazobactam for Gram-negative infections. Diag Microbiol Infect Dis. 2009 ; 64 (2). 236-240
13. Xamplas RC, Itokazu GS, Glowacki RC, et al. Implementation of an extended infusion piperacillin-tazobactam program at an urban teaching hospital. Am J Health Syst Pharm. 2010 ; 67 (8). 622-628